To date 482 patients have been treated with TCI's HeartMate@ left ventricular assist system (LVAS) at 70 clinical centers worldwide. Of those, 433 patients have undergone treatment with the HeartMate IP (implantable pneumatic) LVAS, while 49 patients were treated with the HeartMate VE (vented electric) LVAS. Currently 65 patients are on the HeartMate LVAS: 51 on the pneumatic version and 14 on the electric version. Of the 482 patients, 64% were transplanted after being supported for an average duration of 72 days (range l-503 days) to arrive at a cumulative experience of greater than 100 patient years. Neural incidents occurred in 19% of the patients as a result of a variety of complications, including but not limited to air emboli, seizures, drug reactions, as well as thromboembolic complications whether device-related or not. Device-related complications remain quite low at the 2-3% range with minimal or no anticoagulant therapy. Fourteen patients on the electric version have been discharged to live at home for periods ranging from 1 to 7 months. Patients while being supported have successfully gone back to work or to school. 0 1997 Elsevier Science B.V.
Introduction
The HeartMate Left Ventricular Assist System was originally designed in 1975 designed in . Between 1975 designed in and 1985 it underwent considerable development work to arrive at the design we are currently using. During that period, extensive characterization and reliability testing was carried out as well as the device evaluation in more than 150 large animals. ' The HeartMate Left Ventricular Assist System was originally designed in 1975 . Between 1975 and 1985 it underwent considerable development work to arrive at the design we are currently using. During that period, extensive characterization and reliability testing was carried out as well as the device evaluation in more than 150 large animals.
Methods
In 1985 the clinical study was initiated with the device shown in Fig. 1 . This particular blood pump has a stroke volume of 83 ml and is capable of producing flows of 11 l/min. The pump is of a pusher plate design utilizing 25-mm porcine xenograft valves on both the inlet and outlet conduits to control the blood flow.
A unique characteristic of the device is its bloodcontacting surface. Textured titanium and polyurethane internal blood-contacting surfaces encourage the deposition of a fibrin-cellular matrix derived from the patient's blood. Cells and protein penetrate the pores of the surface to anchor the formed coagulum. With the passage of time, this coagulum restructures to a thin, well-adhered pseudoneointima rich in a variety of cells, including endothe- lial cells lining the surface. Fig. 2 illustrates the surface after 243 days in a human. The need for anticoagulation is greatly reduced with this surface. The recommended drug therapy consists of only 80 mg of aspirin daily with 75 mg of persantine, three times a day. Thromboembolic complications have been remarkably low.
The blood pump can be powered by either air or electrical energy as shown in Fig. 3 . The electrical system incorporates a small electric motor/cam assembly that converts the rotary motion of the motor to axial translation to activate the piston of the blood pump. In emergency situations the system can also be operated with air from either a portable hand pump or the standard pneumatic console. The HeartMate LVAS is designed to be implanted, as shown in Fig. 4 , either in the peritoneal cavity or in a surgically-produced properitoneal pocket. This pocket is surgically created in the left upper quadrant of the abdominal wall under the left rectus muscle and on top of the posterior rectus fascia. The power leads are exited through the abdominal wall to connect to either a pneumatic console or electronic controller and batteries. In the case of the pneumatic system, the patient can use either the hospital-based system as shown in Fig. 5 , or the portable pneumatic system shown in Fig. 6 . The latter system is battery-operated, which will permit patients the freedom to leave the hospital, to live at home, to work or to return to school as our electric patients have been allowed to do.
The electric system is the most portable system now produced in the world. As shown in Fig. 7 , one lead exits from the patient to connect to the miniature electronic controller.
Air is vented through this lead to exhaust at the filter port just prior to the controller. Electrical power is obtained from two small batteries that the patient carries conveniently in a shoulder holster. These provide sufficient energy to power the system from 5 to 10 h, depending on the activity level. 
Results
A clinical study was initiated in 1985 at the Texas Heart Institute. Since that time, additional sites were added in a very controlled fashion to allow sufficient time to learn as much as possible about the system prior to widespread use. Regulatory approvals were obtained both in the United States and Europe as shown in Table 1 . With these approvals in hand, additional sites were brought on as shown in Fig. 8 . It is anticipated that approximately 90 clinical sites worldwide will be using the HeartMate system by the end of 1995.
Implant activities have also increased significantly with approvals. As shown in Fig. 9 , implant activity for the electric (VE) and pneumatic (IP) systems has been Driver is battery-operated and designed to allow patients to be dishcarged from the hospital. It is capable of producing flows of up to 10 ljmin.
Controller
?? l_eft Side Battery Omitted for Clarity Fig. 7 . The VE system is designed for tether-free operation. A single lead exits the body to connect to a miniature System Controller. Power leads exit the Controller and attach to two battery packs worn by the patient.
steadily increasing with 135 completed in 1994. To date, approximately 250 implants have been completed in 1995. Implant activities of the VE system since the initiation of the clinical study has steadily increased as shown in Fig. 10 . In 1994 there were 18 HeartMate VE implants completed while, as of August 1995, 32 additional implants have been carried out. Fig. 11 illustrates the implant duration of the patients who were supported with the HeartMate VE LVAS and who were subsequently transplanted. As shown, 50% were supported for greater than 100 days while 25% were supported for more than 170 days.
vanced. The pneumatic data represents all implants dating back to 1985 while the electric data represents implants that were initiated in 199 1. Improved patient management, coupled with better patient selection, results in improved outcome. The percentage of neural dysfunction shown on the table is for all neural incidents including, but not limited to, air emboli, seizures, drug reactions, as well as thromboembolic complications, whether device-related or not. Devicerelated thromboembolic complications remain quite low at the 2-3% range with minimal or no anticoagulant therapy. Patient data are shown in Tables 2 and 3. To date Patients using the HeartMate VE system may enter we have more than 100 patient years of experience into the Patient Release Program. Table 4 illustrates with these systems and have been able to maintain a the results of this program to date. This clinical study high transplant rate in the US with the pneumatic has been fruitful with patients being discharged to and electric systems. The lower transplant rate shown live at home while they await a transplant. Several for international use in not representative for all patients such as the patient shown in Fig. 12 have countries. Most CE countries have excellent results returned to work, while other younger patients have with only one country with very poor results, lowerreturned to school. This technology was developed to ing the average to 45%. Adverse events for the elecreturn patients to society on a permanent basis as an tric and pneumatic systems are similar with alternative to transplant. The Phase I program of improvements shown in the electric system. These imevaluating the technology as a bridge to transplant proved results indicate that the technology has adhas encouraged us to take the next step, permanent use. Alternative to medical treatment as well as alternative to transplant clinical studies have been started in two countries outside of the US with plans to start an FDA trial in the US in 1995. This FDA trial will take two to three years to complete.
At that point, the HeartMate LVAS should be commercially available for non-transplant candidates.
